Meera J. Desai - May 25, 2023 Form 4 Insider Report for Adamis Pharmaceuticals Corp (ADMP)

Role
Director
Signature
/s/ David C. Benedicto, as Attorney-in-Fact
Stock symbol
ADMP
Transactions as of
May 25, 2023
Transactions value $
$0
Form type
4
Date filed
5/30/2023, 06:15 PM
Previous filing
Oct 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMP Common Stock Award +3.14K 3.14K May 25, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 Received in exchange for common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.